• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Avelox (Moxifloxacin Hydrochloride) Tablet and Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – August 2012

Summary View



Peripheral Neuropathy
  • Rare cases of sensory or sensorimotor axonal polyneuropathy affecting small and/or large axons resulting in paresthesias, hypoesthesias, dysesthesias and weakness have been reported in patients receiving quinolones including Avelox. Avelox should be discontinued if the patient experiences symptoms of neuropathy in order to prevent the development of an irreversible condition